Trial Profile
Randomized phase II study of CPT-11 plus TS-1 plus Cetuximab for advanced and/or recurrent colon cancer which are oxaliplatin-resistant and KRAS wild type (OGSG 0901)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Irinotecan (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms OGSG 0901
- 09 Nov 2009 New trial record